InforSense applications provide the framework for integrating data from an extremely broad range of data sources, for many multinational organisations from pharmaceuticals to finance. InforSense has also developed state of the art applications to integrate genomics, biomarker and clinical data, that provide a unique offering to researchers in the developing areas of translational and personalised medicine. InforSense's founder, Professor Yi ke Guo will take up the role of Chief Innovation Officer at IDBS.
Neil Kipling, CEO and founder of IDBS said, "IDBS has a powerful vision to provide complete data infrastructures for R&D organisations in commercial and academic endeavour. Our existing domain expertise and twenty-year track record is enhanced by the acquisition of InforSense, whose leadership and technologies are globally recognised. This is a major enabling step towards becoming the number one informatics partner of R&D worldwide. An additional facet of this acquisition is the opportunity to cement a strategic informatics research relationship with Imperial College. The combination of our rigorous software development and powerful new research capabilities creates a groundbreaking new organisation."
Mr John O'Connell, Chairman of InforSense said, "As chairman I am delighted to see InforSense become part of a visionary software company with proven expertise in the life sciences domain. The market can only react positively to the emergence of the first single end-to-end R&D informatics solution provider. This acquisition has been enabled by the vision and commitment of founder and CTO, Professor Yike Guo, and by the strong leadership of our management team, under our CEO David Bennett, and is good news for InforSense customers, shareholders and staff".
This announcement comes shortly after IDBS announced the agreement with the University of Cambridge (UK) under which IDBS is to provide data management solutions to the Department of Chemistry, to improve data sharing across its broad network of academic groups in the UK and elsewhere, and marks the start of an ongoing informatics collaboration that will provide leading-edge technologies for commercialisation.